8-KRegulation FDExhibits & Filings

AGILENT TECHNOLOGIES, INC. 8-K Report, Regulation FD Disclosure (Jan 5, 2024)

Filed January 5, 2024For Securities:A

Summary

Agilent Technologies, Inc. (A) has filed an 8-K report on January 5, 2024, to disclose a change in its business segment reporting structure. Effective for the quarter ending January 31, 2024, the company is moving its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG). This strategic reorganization aims to enhance growth opportunities within both affected divisions. This change will result in a restatement of prior period financial information to align with the new segment structure. Investors should note that the report includes selected segment information for historical periods (fiscal quarters and years from 2021 to 2023) reflecting this updated organization, which will be incorporated into future financial statements. The information provided is furnished and not deemed filed under Section 18 of the Securities Exchange Act.

Key Highlights

  • 1Agilent Technologies is reorganizing its business segments, moving the Cell Analysis Division.
  • 2The Cell Analysis Division will be transferred from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG).
  • 3This change is intended to strengthen growth opportunities for both LSAG and DGG.
  • 4The new segment structure will be reflected in financial statements starting with the quarter ending January 31, 2024.
  • 5Prior period financial statements will be recast to conform to the new reporting segments.
  • 6The company is furnishing selected historical segment information (FY2021-2023) reflecting the updated structure.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and provide details about a change in Agilent Technologies' business segment structure. Specifically, the Cell Analysis Division is being moved from one segment to another.

The Cell Analysis Division is moving from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG).

The new segment structure will take effect beginning with the fiscal quarter ending January 31, 2024. Financial statements from this period onwards will reflect the change, with prior periods being restated accordingly.

No, Agilent Technologies will continue to have three reportable business segments: LSAG, DGG, and Agilent CrossLab, even after this internal reorganization.